The Effectiveness and Safety of Triple-Antiplatelet Treatment Based on Cilostazol for Patients Receiving Percutaneous Coronary Intervention: A Meta-Analysis

Authors

  • Ping Wang MS,

    1. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China
    Search for more papers by this author
  • Shijie Zhou MS,

    1. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China
    Search for more papers by this author
  • Rui Zhou PhD,

    1. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China
    2. Department of Electrophysiology, Institute of Cardiovasology, Luzhou Medical College, Luzhou, Sichuan, China
    Search for more papers by this author
  • Gan Liu MM,

    1. Department of Dermatology, The First Hospital, Chongqing Medical University, Chongqing, China
    Search for more papers by this author
  • Ping Tang MS,

    1. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China
    Search for more papers by this author
  • Jing He MS,

    1. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China
    Search for more papers by this author
  • Cong Ma MS,

    1. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China
    Search for more papers by this author
  • Yi He MM,

    1. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China
    Search for more papers by this author
  • Jinliang Yang MD

    Corresponding author
    1. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China
    • State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Keyuan Road 4, No. 1, Chengdu, Sichuan, 610041, China
    Search for more papers by this author

Abstract

The combination of cilostazol, aspirin, and clopidogrel (triple therapy) after percutaneous coronary intervention has been considered as an alternative therapy. We performed a meta-analysis based on 8 randomized controlled trials with a total of 3332 patients to compare the effectiveness and safety of this triple therapy with traditional dual therapy (aspirin and clopidogrel). Our findings suggested that the triple therapy is more effective than dual therapy in preventing restenosis (odds ratio [OR]: 0.52, 95% confidence interval [CI]: 0.40–0.66, P < 0.00001), maintaining minimal lumen diameter (OR: 0.15, 95% CI: 0.10–0.20, P < 0.00001), and avoiding target-vessel revascularization (OR: 0.62, 95% CI: 0.47–0.82, P = 0.001). There is also no significant difference in major adverse cardiac and cerebrovascular events between the 2 therapies, except the smaller occurrence rate of target-lesion revascularization in the triple-therapy group (OR: 0.42, 95% CI: 0.26–0.69, P = 0.0005). However, the triple therapy is associated with a higher level of adverse drug events, including rash (OR: 2.45, 95% CI: 1.41–4.23, P = 0.001), gastrointestinal disorders (OR: 2.59, 95% CI: 1.26–5.30, P = 0.009), and drug discontinuation (OR: 3.80, 95% CI: 1.59–9.10, P = 0.003), but it has no difference in bleeding compared with the dual therapy (OR: 1.05, 95% CI: 0.71–1.55, P = 0.80).

Additional Supporting Information may be found in the online version of this article.

Ping Wang, MS and Shijie Zhou, MS contributed equally to this article. The authors have no funding, financial relationships, or conflicts of interest to disclose.

Ancillary